RPESC-RPE-4W

N/A

Report date: 2022/11/07 19:19:38

Base Information

Drug NameRPESC-RPE-4W

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Source of cells > RPE Stem Cell-derivedCell and gene therapy > Cell therapy > Somatic cell > Retinal pigment epithelial cell therapy

Mechanisms of ActionCell replacements

TargetsNot applicable

Therapy Area/IndicationsGeographic AtrophyMacular Degeneration

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesLuxa Biotechnology LLC

China Registration ClassN/A

Develop Information

Active CompaniesLuxa Biotechnology LLC

Inactive CompaniesN/A

Active IndicationsGeographic AtrophyMacular Degeneration

Inactive IndicationsN/A

Other Information

ATC CodeN/A